BioCentury | Jun 11, 2007
Emerging Company Profile

Novelix: Dogging cancer

...With about 300 small molecule cancer candidates, Novelix Pharmaceuticals Inc. believes it has enough shots on goal to...
...company's founders. The company initially has selected NVX-144 , NVX-188 and NVX-207 for internal development. Novelix...
...the U.S. Novelix received an undisclosed upfront payment and is eligible for milestones and royalties. Novelix...
BioCentury | Jun 11, 2007
Emerging Company Profile

Novelix Pharmaceuticals Inc.

...Novelix Pharmaceuticals Inc. Novelix Pharmaceuticals Inc. Pasadena, Calif. Technology: Small molecule cancer therapeutics Disease focus: Cancer Clinical status...
BioCentury | Mar 5, 2007
Company News

AOP Orphan, Novelix deal

...in preclinical testing and is expected to enter the clinic in 2008 to treat cancer. Novelix...
...milestones and royalties. Further details were not disclosed. AOP Orphan Pharmaceuticals AG , Vienna, Austria Novelix Pharmaceuticals Inc....
BioCentury | Jan 2, 2006
Company News

Novelix, University of Southern California deal

...The university granted Novelix an exclusive license to a group of small molecule cancer therapeutics. The...
...therapeutics. The lead product is NVX-144 , an IL-24 modulator that is in preclinical development. Novelix Pharmaceuticals Inc....
Items per page:
1 - 4 of 4
BioCentury | Jun 11, 2007
Emerging Company Profile

Novelix: Dogging cancer

...With about 300 small molecule cancer candidates, Novelix Pharmaceuticals Inc. believes it has enough shots on goal to...
...company's founders. The company initially has selected NVX-144 , NVX-188 and NVX-207 for internal development. Novelix...
...the U.S. Novelix received an undisclosed upfront payment and is eligible for milestones and royalties. Novelix...
BioCentury | Jun 11, 2007
Emerging Company Profile

Novelix Pharmaceuticals Inc.

...Novelix Pharmaceuticals Inc. Novelix Pharmaceuticals Inc. Pasadena, Calif. Technology: Small molecule cancer therapeutics Disease focus: Cancer Clinical status...
BioCentury | Mar 5, 2007
Company News

AOP Orphan, Novelix deal

...in preclinical testing and is expected to enter the clinic in 2008 to treat cancer. Novelix...
...milestones and royalties. Further details were not disclosed. AOP Orphan Pharmaceuticals AG , Vienna, Austria Novelix Pharmaceuticals Inc....
BioCentury | Jan 2, 2006
Company News

Novelix, University of Southern California deal

...The university granted Novelix an exclusive license to a group of small molecule cancer therapeutics. The...
...therapeutics. The lead product is NVX-144 , an IL-24 modulator that is in preclinical development. Novelix Pharmaceuticals Inc....
Items per page:
1 - 4 of 4